FDA warned Musclepower Enterprise (MONSTER KING/GE LABS) over unapproved SARM drugs and undeclared trendione in GE Labs Ykarine.
What happened
FDA reviewed the company’s websites between March and November 2025 and found GE Labs Ykarine and GE Labs MK 677 offered as SARMs. In March 2025, FDA obtained samples through monsterking.eu and laboratory analysis found GE Labs Ykarine contained undeclared trendione, an anabolic steroid and Schedule III controlled substance. FDA also cited website and label claims as evidence the products are drugs and said they are unapproved new drugs; MK 677 labeling lists ibutamoren.
What FDA found
The products marketed as SARMs are unapproved new drugs because no FDA-approved application is in effect for them.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)GE Labs Ykarine is misbranded because its labeling does not declare that it contains trendione.
FD&C Act section 502(a), 21 U.S.C. 352(a)A sample of GE Labs Ykarine contained undeclared trendione, an anabolic steroid and Schedule III controlled substance.
21 CFR 1308.13(f)(30)GE Labs Ykarine is labeled as a dietary supplement even though NAC is excluded from the dietary supplement definition.
FD&C Act section 201(ff)(3)(B)(i), 21 U.S.C. 321(ff)(3)(B)(i)GE Labs MK 677 is labeled as a dietary supplement even though ibutamoren is excluded from the dietary supplement definition.
FD&C Act section 201(ff)(3)(B)(ii), 21 U.S.C. 321(ff)(3)(B)(ii)Website and label claims, such as increasing muscle mass and acting as a growth hormone secretagogue, show the products are intended to affect body structure or function and are drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the specific steps taken to correct the violations and prevent recurrence, with supporting documents, sent to CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email with firm name and identifier 719339. If correction cannot be completed in that time, the company must explain the delay and give a completion date.
Who should pay attention
- online sellers of bodybuilding and supplement products
- brands or distributors handling SARM or ibutamoren products
- retailers and quality teams reviewing supplement labels and drug claims
This is a summary. Read the original letter on fda.gov.